ALMB-0168 / CSPC Pharma - LARVOL DELTA

Evaluation of the safety and efficacy of ALMB-0168, a novel monoclonal antibody activating Cx43 hemichannel, for osteosarcoma after standard therapy failure: A multicenter, open-label, single agent, phase 1/2 study (ACE study). (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT04886765 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P1/2 data • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed (clinicaltrials.gov) - P2 | N=144 | Not yet recruiting | Sponsor: AlaMab Therapeutics (Shanghai) Inc.

Metastases • New P2 trial • Oncology • Solid Tumor

ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study. (ASCO 2023) - P1/2 | "ALMB-0168 demonstrated encouraging efficacy and tolerable safety in patients with metastatic or unresectable osteosarcoma after standard chemotherapy in a phase 1 dose-escalation trial. Dose escalation is ongoing and dose expansion will start at the potential RP2D levels. Clinical trial information: NCT04886765."

Clinical • Metastases • P1 data • Anemia • Breast Cancer • Hematological Disorders • Infectious Disease • Oncology • Osteosarcoma • Pneumonia • Renal Disease • Respiratory Diseases • Sarcoma • Solid Tumor

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma (clinicaltrials.gov) - P1/2; N=238; Not yet recruiting; Sponsor: AlaMab Therapeutics (Shanghai) Inc.

Clinical • New P1/2 trial • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

CSPC/Alamab's Cx43 antagonist first dosed in Phase I study down under (GBI Health) - "China-based CSPC Pharmaceutical Group Ltd (HKEX:01093) announced first patient dosing of Phase I clinical study for its pipeline drug candidate ALMB-0168 in Australia. The first-in-human dosage escalating study is designed to assess the safety, tolerance, pharmacokinetics and preliminary efficacy of the drug in bone cancer and cancer patients with bone metastases."

Trial status • Oncology